Equillium (EQ) Competitors $0.61 +0.01 (+1.33%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EQ vs. EPRX, RANI, ANIX, ASRT, ADAG, PWUP, CTMX, ANL, ME, and KPTIShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Eupraxia Pharmaceuticals (EPRX), Rani Therapeutics (RANI), Anixa Biosciences (ANIX), Assertio (ASRT), Adagene (ADAG), PowerUp Acquisition (PWUP), CytomX Therapeutics (CTMX), Adlai Nortye (ANL), 23andMe (ME), and Karyopharm Therapeutics (KPTI). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Eupraxia Pharmaceuticals Rani Therapeutics Anixa Biosciences Assertio Adagene PowerUp Acquisition CytomX Therapeutics Adlai Nortye 23andMe Karyopharm Therapeutics Equillium (NASDAQ:EQ) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking. Do analysts recommend EQ or EPRX? Equillium presently has a consensus target price of $5.00, suggesting a potential upside of 722.37%. Eupraxia Pharmaceuticals has a consensus target price of $9.00, suggesting a potential upside of 201.00%. Given Equillium's higher probable upside, equities analysts clearly believe Equillium is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Does the media favor EQ or EPRX? In the previous week, Eupraxia Pharmaceuticals had 1 more articles in the media than Equillium. MarketBeat recorded 1 mentions for Eupraxia Pharmaceuticals and 0 mentions for Equillium. Equillium's average media sentiment score of 0.00 equaled Eupraxia Pharmaceuticals'average media sentiment score. Company Overall Sentiment Equillium Neutral Eupraxia Pharmaceuticals Neutral Which has better earnings and valuation, EQ or EPRX? Equillium has higher revenue and earnings than Eupraxia Pharmaceuticals. Equillium is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$45.91M0.47-$13.34M-$0.14-4.34Eupraxia PharmaceuticalsN/AN/A-$28.22M-$0.72-4.15 Is EQ or EPRX more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% Eupraxia Pharmaceuticals N/A -219.64%-96.00% Do institutionals & insiders have more ownership in EQ or EPRX? 27.0% of Equillium shares are owned by institutional investors. 30.3% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in EQ or EPRX? Equillium received 33 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 83.72% of users gave Equillium an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%Eupraxia PharmaceuticalsOutperform Votes3100.00% Underperform VotesNo Votes SummaryEquillium beats Eupraxia Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.54M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-4.3410.5991.3417.19Price / Sales0.47195.381,117.70116.80Price / CashN/A57.1642.6437.86Price / Book0.955.104.794.78Net Income-$13.34M$151.51M$120.07M$225.60M7 Day Performance-13.75%-2.15%-1.90%-1.23%1 Month Performance-16.14%-3.14%11.45%3.37%1 Year Performance-7.74%11.50%30.63%16.58% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium2.9102 of 5 stars$0.61+1.3%$5.00+722.4%-16.5%$21.54M$45.91M-4.3440Gap DownEPRXEupraxia Pharmaceuticals2.2141 of 5 stars$3.41-0.9%$9.00+163.9%N/A$93.03MN/A-4.7829Positive NewsRANIRani Therapeutics3.4495 of 5 stars$1.61-3.0%$11.71+627.6%-55.1%$92.24M$2.72M-1.57110Positive NewsANIXAnixa Biosciences2.9585 of 5 stars$2.83-0.7%$8.50+200.4%-28.8%$91.07M$210,000.00-7.315ASRTAssertio3.3731 of 5 stars$0.95+3.0%$3.25+242.9%-14.8%$90.50M$125.76M-1.2620Gap DownADAGAdagene2.0012 of 5 stars$2.02-1.9%$5.00+147.5%+13.9%$89.43M$815,746.000.00260PWUPPowerUp AcquisitionN/A$11.43flatN/A+5.7%$88.81MN/A0.00N/ACTMXCytomX Therapeutics4.3209 of 5 stars$1.12+0.9%$5.77+415.4%-18.7%$87.65M$101.21M6.53170News CoveragePositive NewsANLAdlai Nortye1.5882 of 5 stars$2.36+3.1%$9.00+281.4%-75.7%$87.08M$5M0.00127ME23andMe2.38 of 5 stars$3.30-1.5%$9.40+184.8%-81.5%$86.20M$219.64M-0.13770Positive NewsKPTIKaryopharm Therapeutics3.8062 of 5 stars$0.67-4.6%$5.00+648.5%-16.2%$84.30M$148.44M-0.61380 Related Companies and Tools Related Companies Eupraxia Pharmaceuticals Competitors Rani Therapeutics Competitors Anixa Biosciences Competitors Assertio Competitors Adagene Competitors PowerUp Acquisition Competitors CytomX Therapeutics Competitors Adlai Nortye Competitors 23andMe Competitors Karyopharm Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EQ) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
